Bruger:Bob Collowân/Værksted 1: Forskelle mellem versioner
Content deleted Content added
Nyt projekt |
Tilføjelser |
||
Linje 1:
{{ Infoboks Lægemiddel
'''Remdesivir''' is a [[Broad-spectrum antiviral drug|broad-spectrum]] [[antiviral medication]] developed by the [[biopharmaceutical]] company [[Gilead Sciences]].<ref name="Scavone_2020">{{cite journal | vauthors = Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A | display-authors = 6 | title = Current pharmacological treatments for COVID-19: what's next? | journal = British Journal of Pharmacology | date = April 2020 | pmid = 32329520 | doi = 10.1111/bph.15072 |doi-access=free }}</ref> As of 2020, remdesivir is being tested as a specific treatment for [[COVID-19]], and has been authorized for emergency use in the U.S. and approved for use in Japan for people with severe symptoms.<ref name="FDA_EUA">{{cite web | title = Remdesivir EUA Letter of Authorization | url = https://www.fda.gov/media/137564/download | format = PDF | website = U.S. [[Food and Drug Administration]] (FDA) | date = 1 May 2020 | access-date = 1 May 2020}} {{PD-notice}}</ref><ref name="FDA EUA PR" /><ref name=":0">{{Cite web|title=Japan approves remdesivir for COVID-19 despite uncertainties|url=http://www.asahi.com/ajw/articles/13358075|website=The Asahi Shimbun|access-date=2020-05-09}}</ref> It may shorten the time it takes to recover from the infection.<ref name="Hopkins"/> Treatment is given by [[intravenous|injection into a vein]].<ref>{{cite web |title=Remdesivir |url=https://www.drugs.com/ppa/remdesivir.html |website=Drugs.com |access-date=30 April 2020}}</ref><ref name="Mehta2020">{{cite journal | vauthors = Mehta N, Mazer-Amirshahi M, Alkindi N | title = Pharmacotherapy in COVID-19; A narrative review for emergency providers | journal = The American Journal of Emergency Medicine | pages = S0735-6757(20)30263-1 | date = April 2020 | pmid = 32336586 | doi = 10.1016/j.ajem.2020.04.035 | pmc = 7158837 | doi-access=free }}</ref>▼
| Navn = Remdesivir
| BilledFil = Remdesivir.svg
| BilledStørrelse = 190px
<!-- Generelt -->
| IUPACNavn =
| HandelsNavne =
| Udlever =
<!-- Identifikatorer -->
| ATCKodePræfiks = Ingen
| ATCKodeSuffiks =
| DrugBank = DB14761
| PubChem = 121304016
| CASNr = 1809249-37-3
| InChI = 1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
| InChIKey = RWWYLEGWBNMMLJ-YSOARWBDSA-N
| SMILES = CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC
<!-- Kemiske data -->
| Formel = C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>8</sub>P
| Molarmasse = 602,585 g/mol
| Smeltepunkt =
<!-- Farmakokinetiske data -->
| AdminVej = Intravenøs
| Biotilgæng =
| Metabolisme =
| Halvtid =
| Udskil =
| ProtBind =
}}
'''Remdesivir''' er et bredspektret [[antiviral]]t [[lægemiddel]] udviklet af det [[USA|amerikanske]] medicinalfirma [[Gilead Sciences]].<ref name="Scavone_2020">{{cite journal | vauthors = Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A | display-authors = 6 | title = Current pharmacological treatments for COVID-19: what's next? | journal = British Journal of Pharmacology | date = April 2020 | doi = 10.1111/bph.15072 |doi-access=free }}</ref> Det blev oprindeligt udviklet til behandling af [[hepatitis C]], men er siden blevet testet på andre [[virus|vira]] som [[ebolavirus]] og [[COVID-19]]. Ved et studium, der bl.a. inkluderede danske COVID-19-patienter,<ref>https://www.dr.dk/nyheder/indland/professorer-begejstrede-nyt-studie-foerste-gang-kan-vi-behandle-coronavirus#!/ </ref> blev der påvist et fald i [[dødelighed]]en fra 11,9 % hos patienter, der fik givet [[placebo]], til 7,1 % hos patienter, der fik givet Remdesivir.<ref name="NEJM">{{cite journal | vauthors = John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., | display-authors = 6 | title = Remdesivir for the Treatment of Covid-19 — Preliminary Report | journal = New England Journal of Medicine | date = 22. maj 2020 | doi = 10.1056/NEJMoa2007764 |doi-access=free }}</ref> Medianhelbredelsestiden blev derudover reduceret fra 15 til 11 dage.<ref name="NEJM"/>
▲
<!-- Side effects and mechanism -->
Side effects may include liver inflammation and an infusion-related reaction with nausea, [[Hypotension|low blood pressure]], and sweating.<ref>{{cite web |title=Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19) |url=https://www.fda.gov/media/137565/download |website=FDA |access-date=8 May 2020}}</ref> It is a [[pro-drug]] that is converted in the body into [[GS-441524]], a [[ribonucleotide]] analog.
<!-- History -->
Earlier studies found antiviral activity against several [[RNA virus]]es including [[SARS coronavirus]] and [[Middle East respiratory syndrome-related coronavirus|MERS coronavirus]], but it is not approved for any indication.<ref name="Scavone_2020" /><ref name="FDA_EUA" /> Remdesivir was originally developed to treat [[hepatitis C]]<ref name="Stephens" /> and was then tested against [[Ebola virus disease]] and [[Marburg virus disease]], but was ineffective for all of these viral infections.<ref name="Scavone_2020"/>
== Referencer ==
{{reflist}}
| |||